Stay updated with breaking news from Albert Bourla. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Future of Everything Festival brings together global newsmakers to discuss trends and opportunities across business, technology, finance, government and culture.
Pfizer reports Q1 results: adjusted EPS beats estimates, driven by revenue growth. Significant declines in Comirnaty and Paxlovid revenues countered by operational gains. Company announces plans for direct-to-consumer online platform.
On Wednesday, Pfizer Inc. (NYSE:PFE) reported first-quarter adjusted EPS of $0.82, down 33% year over year, beating the consensus of $0.54. The company witnesses a significant decrease in Comirnaty and Paxlovid revenues globally and an unfavorable impact of foreign exchange of $107 million, or 1%. The U.S. drugmaker reported sales of $14.9 billion, down 20%, beating the consensus of $14.2 billion. Excluding contributions from Comirnaty and Paxlovid, revenues totaled $12.5 billion, an increase of
14:19 ET -- Pfizer is one of the most mentioned companies in the U.S. across all news items in the past 12 hours, according to Factiva data. The New York-based biopharmaceutical firm said...
Pfizer had a surprise beat in its COVID portfolio despite dim forecasts, but the company is still not feeling the love in its stock.